// App-Quantinova.ai

784 : Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)

Researchers

Presenter

  • Alexander E. Perl

Principal Investigators

  • Siddhartha Ganguly

  • Samer K. Khaled

  • Alwin Krmer

  • Giovanni Martinelli

  • Nigel H. Russell

  • Ken C. Chang

  • Kazunobu Kato

  • Yuhu Yan

  • Li-An Xu

  • Sergey Korkhov

  • Tobias Gnnel

  • Hiroyuki Sumi

  • Arnaud Lesegretain

  • Flora Berisha

  • Derek Mires

  • Aziz Benzohra

  • Takeshi Isoyama

  • Cedric Dos Santos

  • Mark J. Levis

Medical Centers

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • University of Kansas Health System, Kansas City, KS

  • City of Hope National Medical Center, Duarte, CA

  • University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Daiichi Sankyo, Basking Ridge, NJ

  • Precision Medicine, Frederick, MD

  • Daiichi Sankyo Co., Ltd., Tokyo, Japan

  • Daiichi Sankyo France SAS, Paris, France

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

Locations

  • United States

  • Germany

  • Italy

  • United Kingdom

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • quizartinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved